Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Common variation in the NOS1AP gene is associated with drug-induced QT prolongation and ventricular arrhythmia.

Jamshidi Y, Nolte IM, Dalageorgou C, Zheng D, Johnson T, Bastiaenen R, Ruddy S, Talbott D, Norris KJ, Snieder H, George AL, Marshall V, Shakir S, Kannankeril PJ, Munroe PB, Camm AJ, Jeffery S, Roden DM, Behr ER.

J Am Coll Cardiol. 2012 Aug 28;60(9):841-50. doi: 10.1016/j.jacc.2012.03.031. Epub 2012 Jun 6.

2.

Cardiovascular drugs inducing QT prolongation: facts and evidence.

Taira CA, Opezzo JA, Mayer MA, Höcht C.

Curr Drug Saf. 2010 Jan;5(1):65-72. Review.

PMID:
20210721
3.

Understanding drug-induced torsades de pointes: a genetic stance.

Kannankeril PJ.

Expert Opin Drug Saf. 2008 May;7(3):231-9. doi: 10.1517/14740338.7.3.231 . Review.

PMID:
18462182
4.

Torsade de pointes with amiodarone in a patient with previous torsade during beta-receptor blockade.

Skanes AC, Morton BC, Green MS, Tang AS.

Can J Cardiol. 1997 Apr;13(4):383-6. Review.

PMID:
9141970
5.

[Torsades de pointes ventricular tachycardia induced by intravenous amiodarone].

Makai A, Rudas L, Liszkai G, Fazekas T.

Orv Hetil. 2003 Feb 2;144(5):241-7. Review. Hungarian.

PMID:
12647553
6.
7.

Drug-induced arrhythmia: pharmacogenomic prescribing?

Behr ER, Roden D.

Eur Heart J. 2013 Jan;34(2):89-95. doi: 10.1093/eurheartj/ehs351. Epub 2012 Oct 22. Review.

8.

The genetics of pro-arrhythmic adverse drug reactions.

Petropoulou E, Jamshidi Y, Behr ER.

Br J Clin Pharmacol. 2014 Apr;77(4):618-25. doi: 10.1111/bcp.12208. Review.

9.

[QTc-prolonging drugs and the risk of sudden death].

Reingardiene D, Vilcinskaite J.

Medicina (Kaunas). 2007;43(4):347-53. Review. Lithuanian.

10.

Pharmacogenomics and acquired long QT syndrome.

Aerssens J, Paulussen AD.

Pharmacogenomics. 2005 Apr;6(3):259-70. Review.

PMID:
16013957
11.

Drug-induced QT prolongation and sudden death.

Del Rosario ME, Weachter R, Flaker GC.

Mo Med. 2010 Jan-Feb;107(1):53-8. Review.

PMID:
20222297
12.

Antiarrhythmic drugs and torsade de pointes.

Lazzara R.

Eur Heart J. 1993 Nov;14 Suppl H:88-92. Review.

PMID:
8293758
13.

Cellular basis of drug-induced torsades de pointes.

Roden DM.

Br J Pharmacol. 2008 Aug;154(7):1502-7. doi: 10.1038/bjp.2008.238. Epub 2008 Jun 16. Review.

14.

[Ventricular pro-arrhythmic effects of anti-arrhythmia drugs].

Jaillon P, Simon T.

Therapie. 1992 May-Jun;47(3):187-92. Review. French.

PMID:
1295119
15.

Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias.

Shantsila E, Watson T, Lip GY.

Europace. 2007 Sep;9 Suppl 4:iv37-44. Review.

PMID:
17766322
16.

Pharmacologic agents associated with QT interval prolongation.

Olsen KM.

J Fam Pract. 2005 Jun;Suppl:S8-S14. Review.

PMID:
15938993
17.

Current status of class III antiarrhythmic drug therapy.

Roden DM.

Am J Cardiol. 1993 Aug 26;72(6):44B-49B. Review.

PMID:
8256755
18.

Pharmacogenetic issues in thorough QT trials.

Judson RS, Salisbury BA, Reed CR, Ackerman MJ.

Mol Diagn Ther. 2006;10(3):153-62. Review.

PMID:
16771601
19.

QT-interval prolonging drugs: mechanisms and clinical relevance of their arrhythmogenic hazards.

Zehender M, Hohnloser S, Just H.

Cardiovasc Drugs Ther. 1991 Apr;5(2):515-30. Review.

PMID:
1854661
20.

Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges.

Wilke RA, Lin DW, Roden DM, Watkins PB, Flockhart D, Zineh I, Giacomini KM, Krauss RM.

Nat Rev Drug Discov. 2007 Nov;6(11):904-16. Review. Erratum in: Nat Rev Drug Discov. 2008 Feb;7(2):185.

Supplemental Content

Support Center